Lupin, Cornerstone end co-development tie-up in US

New Delhi, Dec 27 (UNI) Drug maker Lupin Ltd today said that the company has mutually ended the agreement with US-based Cornerstone BioPharma to co-develop an antiinfective for the United States market.

The company had entered into the agreement in May 2005.

Lupin plans to continue the product development programme and will seek a partner to market the product to primary care physicians in the US, it said in a statement.

Yesterday rpt yesterday, company's US subsidiary, Lupin Pharmaceuticals, mutually ended an agreement with Chester Valley Pharmaceuticals in the United States to promote Atopiclair -- nonsteroidal cream to pediatricians.

UNI PKS DKS HT1915